NOW FDA APPROVED

Learn More

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250165 07/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
    • Pricing
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
    • Pricing
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences

Apr 5, 2017

Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights

Mar 31, 2017

Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences

Mar 13, 2017

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

Mar 8, 2017

Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference

Mar 7, 2017

Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai

Mar 3, 2017

Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit

Feb 23, 2017

Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress

Feb 21, 2017

Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017

Feb 17, 2017

Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017

Feb 7, 2017
RSS
    • 1...
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • ...32

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use